| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 06/01/2006 | US20060116374 substituted bis/thiohydrazide amide compound; synergistic effect with taxol or taxotere, anticancer agents, side effect reduction |
| 06/01/2006 | US20060116366 Spirocyclic ureas, compositions containing such compounds and methods of use |
| 06/01/2006 | US20060115522 Pharmaceutical composition |
| 06/01/2006 | US20060115489 Influenza immunogen and vaccine |
| 06/01/2006 | US20060115480 Disease treatment via antimicrobial peptide inhibitors |
| 06/01/2006 | US20060115434 Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same |
| 06/01/2006 | DE19849107B4 Verfahren zur Entfernung von unerwünschten, endogen vorhandenen toxischen Alkaloiden aus Pflanzen oder aus pflanzlichen Zubereitungen A method for removing unwanted endogenously present toxic alkaloids from plants or herbal preparations |
| 05/31/2006 | EP1661881A2 Compound capable of binding s1p receptor and pharmaceutical use thereof |
| 05/31/2006 | EP1661579A2 Method for treating diseases associated with changes of qualitative and/ quantitative composition of blood extracellular dna |
| 05/31/2006 | EP1660686A2 Hpv cd8+ t-cell epitopes |
| 05/31/2006 | EP1660669A2 Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives and vicinal cyano, hydroxy substituted carboxylic acid esters |
| 05/31/2006 | EP1660663A2 Methods and compositions for tissue repair |
| 05/31/2006 | EP1660533A2 Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
| 05/31/2006 | EP1660522A2 Pharmaceutical composition with increased bioavailability suitable for the administration of oral retroviral protease inhibitors. process for preparing a concentrate pharmaceutical composition comprising a retroviral protease inhibitor |
| 05/31/2006 | EP1660513A2 A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
| 05/31/2006 | EP1660512A2 Oligonucleotide synthesis with alternative solvents |
| 05/31/2006 | EP1660506A2 Oral neurotherapeutic cefazolin compositions |
| 05/31/2006 | EP1660459A2 Arylsulfonamidobenzylic compounds |
| 05/31/2006 | EP1660181A2 Treatment of age-related macular degeneration |
| 05/31/2006 | EP1660176A2 Optimization of impedance signals for closed loop programming of cardiac resynchornization therapy devices |
| 05/31/2006 | EP1660128A2 Anti-fcrn antibodies for treatment of auto/allo immune conditions |
| 05/31/2006 | EP1660122A2 Immunostimulatory combinations and treatments |
| 05/31/2006 | EP1660112A2 Orally administered small peptides synergize statin activity |
| 05/31/2006 | EP1660110A2 Therapeutic vaccine compositions for the treatment of type 1 diabetes |
| 05/31/2006 | EP1660109A2 Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| 05/31/2006 | EP1660088A2 Pyridomorphinans, pyridazinomorphinans and use thereof |
| 05/31/2006 | EP1660083A2 Stable pharmaceutical composition of rabeprazole |
| 05/31/2006 | EP1660079A2 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia |
| 05/31/2006 | EP1660075A2 Protective and therapeutic uses for tocotrienols |
| 05/31/2006 | EP1660073A2 Hydrophobic drug compositions containing reconstitution enhancer |
| 05/31/2006 | EP1660069A2 Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer's disease and retinal degeneration |
| 05/31/2006 | EP1660045A2 Topical delivery system containing colloidal crystalline arrays |
| 05/31/2006 | EP1660043A2 Immediate-release formulation of acid-labile pharmaceutical compositions |
| 05/31/2006 | EP1660039A2 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 05/31/2006 | EP1660017A2 Amino acid prodrugs |
| 05/31/2006 | EP1660016A2 Sars nucleic acids, proteins, vaccines, and uses thereof |
| 05/31/2006 | EP1660014A2 Rage-related methods and compositions for treating glomerular injury |
| 05/31/2006 | EP1660013A2 Protein biomaterials and biocoacervates and methods of making and using thereof |
| 05/31/2006 | EP1660012A2 Cellular depolarization and regulation of matrix metalloproteinases |
| 05/31/2006 | EP1660011A2 Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders |
| 05/31/2006 | EP1660010A2 Compositions and methods for restoring sensitivity to treatment with her2 antagonists |
| 05/31/2006 | EP1660009A2 Methods for the treatment of endometriosis |
| 05/31/2006 | EP1660008A2 Therapeutic use of g53135-05(fgf-20) in radiation protection |
| 05/31/2006 | EP1660007A2 Compositions for diabetes treatment and prophylaxis |
| 05/31/2006 | EP1446122B1 Use of flibanserin in the treatment of sexual desire disorders |
| 05/31/2006 | EP1345922B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1196183B1 Oregano-based therapeutic composition |
| 05/31/2006 | EP0911342B1 Novel protein and process for producing the same |
| 05/31/2006 | CN1781019A Animal model simulating neurologic disease |
| 05/31/2006 | CN1780838A Azabicyclononene derivatives |
| 05/31/2006 | CN1780811A Diphenylethylene compounds and uses thereof |
| 05/31/2006 | CN1780663A 9-azabicyclo nonylene derivatives with a heteroatom at the 3-position as renin inhibitors |
| 05/31/2006 | CN1780659A Extracorporeal pathogen reduction system |
| 05/31/2006 | CN1780640A Attenuated strains of vibrio cholerae and lyophilised vaccines containing same |
| 05/31/2006 | CN1780633A Pharmaceutical compositions for treating painful neuropathy and methods of treating same |
| 05/31/2006 | CN1780624A Tetracyclic benzamide derivatives and methods of use thereof |
| 05/31/2006 | CN1780614A Compounds for the treatment of metabolic disorders |
| 05/31/2006 | CN1780596A Random and non-random alkylene oxide polymer alloy compositions |
| 05/31/2006 | CN1780556A Treating hepatocellular carcinomas using therapeutic viruses |
| 05/31/2006 | CN1780555A Nasal administration of the LH-RH analog leuprolide |
| 05/31/2006 | CN1257892C New indole derivatives with 5-HT6 receptor affinity |
| 05/30/2006 | US7053073 Treatment for reactive arthritis or bursitis |
| 05/30/2006 | US7052688 At least one strain of hydrogen peroxide-producing lactic acid bacteria, and at least one strain of arginine-utilizing lactic acid bacteria; treatment of infections and inflammatory conditions caused by bacteria, viruses, fungi |
| 05/26/2006 | WO2006054931A1 The use and identification of antagonists of protease-activated receptor 3 (par3) in the treatment of asthma |
| 05/26/2006 | WO2006054288A1 Polymeric nano-shells |
| 05/26/2006 | WO2005120435A3 Method for preparing sustained release compositions and the use of said compositions for treating chronic diseases of central nervous system (cns) |
| 05/26/2006 | WO2005020880A3 Methods for the treatment of endometriosis |
| 05/26/2006 | WO2004091534A3 Inhibitors of n ethylmaleimide sensitive factor |
| 05/26/2006 | WO2004084835A3 Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor |
| 05/26/2006 | WO2004056316A3 Vaccines against hiv-1 tat protein to generate neutralizing antibodies |
| 05/26/2006 | WO2004037204A3 Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
| 05/25/2006 | US20060111848 Identification and use of cofactor independent phosphoglycerate mutase as a drug target for pathogenic organisms and treatment of the same |
| 05/25/2006 | US20060111585 Title of the invention n-cyclohexylaminocarbonyl benzensulfonmide derivatives |
| 05/25/2006 | US20060111426 Indole-3-sulphur derivaties |
| 05/25/2006 | US20060111425 To treat diseases of respiratory, urinary and gastrointestinal systems; highly selective; significant potency; (2R,2S)(1 alpha ,5 alpha ,6 alpha )-N-{-[4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-3-azabicyclo[3.1.0]hex-6-yl-methyl}-2-hydroxy-2-cyclopentyl-2-phenylacetamide |
| 05/25/2006 | US20060111401 Taxanes having a C10 carbonate substituent |
| 05/25/2006 | US20060111319 Use of dextran sulfate |
| 05/25/2006 | US20060111293 Antagonists for human prolactin |
| 05/25/2006 | US20060110740 Use of sendai virus as a human parainfluenza vaccine |
| 05/25/2006 | US20060110736 Hiv vaccine formulations |
| 05/25/2006 | US20060110470 Pharmaceutical formulation of traditional chinese medicine for abstinence of drug and preparation method and use thereof |
| 05/25/2006 | US20060110410 Recombinant toxin fragments |
| 05/25/2006 | US20060110388 ß binding molecules |
| 05/25/2006 | US20060110381 comprising a continuous, biocompatible liquid phase, a solid phase comprising porous or non-porous particles of a biocompatible polymer suitable for use in hemostasis and which are substantially insoluble in the liquid phase, and sterile thrombin |
| 05/24/2006 | EP1658856A1 Exendins for glucagon suppression |
| 05/24/2006 | EP1658854A2 Formulations useful in the treatment of male and female impotence |
| 05/24/2006 | EP1658852A1 Oral pharmaceutical preparation containing ibandronat |
| 05/24/2006 | EP1658301A2 N-desmethyl-n-substituted-11-deoxyerythromycin compounds |
| 05/24/2006 | EP1658290A2 Compounds and compositions as protein kinase inhibitors |
| 05/24/2006 | EP1658274A2 Inhibitors of cathepsin s |
| 05/24/2006 | EP1658267A2 Inhibitors of cathepsin s |
| 05/24/2006 | EP1658109A2 Ocular drug delivery device |
| 05/24/2006 | EP1658089A2 Compositions for treating pathologies that necessitate suppression of gastric acid secretion |
| 05/24/2006 | EP1658077A2 Dual function compounds and uses thereof |
| 05/24/2006 | EP1658075A2 Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis |
| 05/24/2006 | EP1658037A2 Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor |
| 05/24/2006 | EP1658036A2 Estrogen receptor modulators and uses thereof |
| 05/24/2006 | EP1658035A2 Delivery of immune response modifier compounds |
| 05/24/2006 | EP1658034A2 Antibiotic product, use and formulation thereof |
| 05/24/2006 | EP1657980A1 Anti-virus hydrophilic polymeric material |